An open label extension study of Varoglutamstat to patients who have been treated under VIVIAD or VIVA-MIND protocols
Latest Information Update: 29 Apr 2024
At a glance
- Drugs Varoglutamstat (Primary)
- Indications Alzheimer's disease; Cognition disorders; Mild cognitive impairment
- Focus Therapeutic Use
- Acronyms VIVALONG
Most Recent Events
- 24 Apr 2024 According to a Vivoryon Therapeutics media release, In line with the Companys cost reduction measures and given the developments of VIVIAD and VIVA-MIND, Vivoryon has decided to stop VIVALONG OLE study preparation activities
- 26 Oct 2023 According to a Vivoryon Therapeutics media release, the company has commenced preparations for an open-label extension (OLE) study I July 2023, to provide a long-term treatment option to patients after completion of treatment under the VIVIAD or VIVA-MIND protocol.
- 18 Jul 2023 New trial record